In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

In its Phase 3 trial conducted in China, Ivonescimab shattered expectations, reducing the risk of disease progression or death by 49% compared to Merck’s Keytruda (pembrolizumab). With a nearly ...

The FDA approves subcutaneous formulation of RHHBY's leading immunotherapy drug, Tecentriq, under the brand name Tecentriq ...

Summit Therapeutics (NASDAQ: SMMT) recently reported Ivonescimab’s Phase 3 results from study conducted in China that showed significant efficacy in addressing NSCLC treatment ...

"Our key data presentations highlight our scientific leadership in developing targeted therapies, including small molecules and antibody-drug conjugates ... ADC disitamab vedotin in combination with ...

The company's top-selling drug, Keytruda, took over from Humira as the ... should also deliver many more brand-new medicines moving forward. Though its sales will almost certainly decline once ...

Three Fool.com contributors were asked to recommend some no-brainer dividend stocks to buy in September. They selected healthcare companies AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Pfizer (NYSE: ...

The company's crown jewel is the best-selling drug in the world, a title it officially took last year. However, Keytruda will be ... and can develop brand-new medicines through innovations.